$PEPG

PepGen stock tumbles 44% on disappointing trial results

PepGen Ltd (NASDAQ:PEPG) shares dropped 44% after-hours following disappointing Phase 2 trial results for its myotonic dystrophy type 1 treatment, PGN-EDODM1. The drug showed an average splicing correction of 7.3% compared to placebo, with an outlier patient significantly impacting the overall mean. Despite the setback, the company plans to report data from a higher dose cohort in late 2026 and has sufficient funding into mid-2027.

Original reporting
Investing.com · Investing.com
Published Mar 31, 2026, 2:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PepGen stock tumbles 44% on disappointing trial results — source image
Decision brief

The 30-second read

$PEPGBearishMed
01

Why it matters

Disappointing trial results have led to a sharp stock decline, affecting investor confidence and valuation.

02

Market read

The news has immediate relevance for investors in PepGen and similar biotech firms, influencing stock prices and investor sentiment.

03

What to watch

Potential for company to improve outcomes with ongoing research; broader market conditions may influence recovery.

Timing: Immediate, given the recent stock decline and upcoming trial data.

Background

PepGen is developing therapies for neuromuscular disorders, with PGN-EDODM1 targeting myotonic dystrophy type 1.

Company-level read

Ticker impact

$PEPGBearishMedium confidence
Context

High relevance due to recent stock price movement and trial results.

Expected impact

Potential further decline in short-term, with possible stabilization or recovery if upcoming data shows improvement.

Evidence & confidence

The substantial stock drop indicates strong negative sentiment; however, the company's plans for higher dose data and existing funding could lead to stabilization.

Market effects

Negative impact on biotech and life sciences sectors, especially companies with similar trial profiles.

Potential regional effects in US biotech markets.

Limited, primarily affecting US-based biotech stocks.

Counterpoint

The stock may have overreacted; positive news from higher dose cohorts could reverse the trend.

Key entities

  • PepGen Ltd

    Biotech company focused on genetic medicines for neuromuscular diseases.

  • PGN-EDODM1

    Experimental therapy for myotonic dystrophy type 1.

Related articles

$PEPGMed

PepGen Inc. (PEPG): Results of Operations and Financial Condition

PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights – DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg t

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.